Trial · NCT00231868
A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
NCT00231868, Phase 2, Completed, Montefiore Medical Center; results first posted 2020-08-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma. Trials, record NCT00231868. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00231868
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
- NCT number
- NCT00231868
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 81 participants, actual
- Lead sponsor
- Montefiore Medical Center
- Conditions
- Uterine Cancer
- Interventions
- Carboplatin and Paclitaxel and Pelvic Radiation Therapy, Carboplatin and Paclitaxel and Pelvic Radiation Therapy, Carboplatin and Paclitaxel and Radiation Therapy
- First posted
- 2005-10-04
- Last updated
- 2020-08-12
- Results first posted
- 2020-08-12
- Limitations and caveats
- There are minor differences in the carboplatin doses between the current trial and our pilot study.~This is a single institution trial. A limited number of advanced stage patients was accrued.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC | Up to 7 years | Overall survival analysis of early stage (stage 1 \& 2) and late stage (stage 3 \& 4)UPSC patients who were prescribed radiation "sanwhiched" between three cycles of paclitaxel/platinum chemotherapy before and after RT. Outcome measures were Progression Free Survival (PFS) and Overall Survival (OS). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | To Evaluate the Toxicity and Tolerability of Pelvic Radiation Sandwiched Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC | Up to 7 years | Kaplan-Meier survival analysis of Progression Free Survival (PFS) and Overall Survival (OS). | months | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| To Evaluate the Toxicity and Tolerability of Pelvic Radiation Sandwiched Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC | Drug:Carboplatin, Paclitaxel & Radiation | Early stage (PFS) | 65.5 | Standard Error 3.6 | months |
| To Evaluate the Toxicity and Tolerability of Pelvic Radiation Sandwiched Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC | Drug:Carboplatin, Paclitaxel & Radiation | Late stage (PFS) | 25.8 | Standard Error 3.0 | months |
| To Evaluate the Toxicity and Tolerability of Pelvic Radiation Sandwiched Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC | Drug:Carboplatin, Paclitaxel & Radiation | Early stage (OS) | 76.5 | Standard Error 4.3 | months |
| To Evaluate the Toxicity and Tolerability of Pelvic Radiation Sandwiched Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC | Drug:Carboplatin, Paclitaxel & Radiation | Late stage (OS) | 35.9 | Standard Error 5.3 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Carboplatin & Paclitaxel & Radiation: Pelvic Radiation Therapy | 81 | |
| Overall Study | COMPLETED | Carboplatin & Paclitaxel & Radiation: Pelvic Radiation Therapy | 65 | |
| Overall Study | NOT COMPLETED | Carboplatin & Paclitaxel & Radiation: Pelvic Radiation Therapy | 16 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Carboplatin & Paclitaxel & Radiation: Pelvic Radiation Therapy | 16 | 72 |
| Total, other adverse events | Carboplatin & Paclitaxel & Radiation: Pelvic Radiation Therapy | 0 | 72 |
| Total, serious adverse events | Carboplatin & Paclitaxel & Radiation: Pelvic Radiation Therapy | 0 | 72 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22035806 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00231868
GET https://conductscience.org/api/trials/v1/NCT00231868/registered